PD2M Meet the Leader Forum: Dr. Patricia Hurter

Originally delivered Jan 25, 2023
Source: AIChE
  • Type:
    Archived Webinar
  • Level:
    Intermediate
  • Duration:
    1 hour

Share This Post:

Dr. Patricia Hurter serves as CEO of Lyndra Therapeutics, a biotechnology company pioneering oral long-acting therapies to make daily pills a thing of the past. Lyndra’s lead product is oral weekly risperidone for schizophrenia and bipolar disorder, with several other products in development.

Prior to Lyndra, she spent 15 years at Vertex, bringing multiple breakthrough therapies to market. At Vertex, her team designed and built the world’s first fully continuous drug product manufacturing plant, approved by the FDA in 2015. Before joining Vertex, Dr. Hurter was Director of Formulation at Merck, where she was a key member of the early development team for Januvia®.

Dr Hurter serves on the Board of Directors of Lyndra Therapeutics, and Synlogic Therapeutics, a publicly traded company pioneering the application of synthetic biology to design living therapeutics. She is a member of the Advisory Board of the Taubman Center for State and Local Government at the Harvard Kennedy Center. She holds a Ph.D. in chemical engineering from MIT, an M.S. in mechanical engineering from WVU and a B.Sc. in chemical engineering, cum laude, from the University of KwaZulu-Natal (South Africa). She is a member of the National Academy of Engineering.

This Live Event was conducted on Wednesday, January 25, 2023, 11:00am EST and is now being archived for On-Demand viewing. The process typically takes 3-4 days.

Checkout

Checkout

Do you already own this?

Webinar content is available with the kind permission of the author(s) solely for the purpose of furthering AIChE’s mission to educate, inform and improve the practice of professional chemical engineering. All other uses are forbidden without the express consent of the author(s).